Zydus Lifesciences gets USFDA nod for asthma treatment drug
The approval by the US Food and Drug Administration (USFDA) is for Theophylline extended-release tablets of strengths 300 mg and 450 mg, Zydus Lifesciences said in a regulatory filing.
Theophylline extended-release tablets, 300 mg and 450 mg had annual sales of USD 12.6 million in the US. Representational image. Source: Pexels